within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC53_TegafurCombinations;

model TegafurCombinations
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.42,
    Cl = 3.1944444444444443e-06,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.048,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01,
    Tlag = 600,
    Vdp = 0.122,
    k12 = 7.222222222222223e-06,
    k21 = 7.222222222222223e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>TegafurCombinations</td></tr><tr><td>ATC code:</td><td>L01BC53</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>48</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tegafur, in combinations (ATC L01BC53), is an oral chemotherapeutic agent used mainly in conjunction with other agents such as uracil or gimeracil and oteracil (as S-1 formulation) for the treatment of various solid tumors, especially gastric and colorectal cancer. It is a prodrug of 5-fluorouracil (5-FU) that is bioactivated in the body, and these combinations are approved and still in clinical use for several cancer indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (mixed sex, typical age range 40-70 years) receiving S-1 (tegafur/gimeracil/oteracil) orally.</p><h4>References</h4><ol><li><p>Kobuchi, S, et al., &amp; Sakaeda, T (2018). Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 123 452–458. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2018.08.004\">10.1016/j.ejps.2018.08.004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30077713/\">https://pubmed.ncbi.nlm.nih.gov/30077713</a></p></li><li><p>Zuo, L, et al., &amp; Chen, R (2024). Establishment and validation of a population pharmacokinetic model for apatinib in patients with tumors. <i>BMC cancer</i> 24(1) 1346–None. DOI:<a href=\"https://doi.org/10.1186/s12885-024-13118-4\">10.1186/s12885-024-13118-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39487410/\">https://pubmed.ncbi.nlm.nih.gov/39487410</a></p></li><li><p>Shirao, K, et al., &amp; Abbruzzese, JL (2004). Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 22(17) 3466–3474. DOI:<a href=\"https://doi.org/10.1200/JCO.2004.05.017\">10.1200/JCO.2004.05.017</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15277535/\">https://pubmed.ncbi.nlm.nih.gov/15277535</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01BC53 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end TegafurCombinations;
